Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists

PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at the interactive ePoster session during the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) being held May 6 - 9, 2017 in San Diego, CA.

The SECURE study evaluated the clinical benefit of the investigational transdermal contraceptive patch AG200-15, known as Twirla®, in a diverse, real-world population of women reflective of current weight trends in the United States. The ePoster will include efficacy and safety findings for the overall population and pre-specified body mass index (BMI) categories, in addition to results on the bleeding profile that have not previously reported.

The presentation details are as follows:

Poster Title: Results from the SECURE Trial, a Phase 3 Study of the AG200-15 
 Investigational Transdermal Contraceptive Patch
Poster ID: 22A 
Poster Session: ePoster Session A
Room:Ballroom 20A
Date and Time:Saturday, May 6, 2017
Time:11:00 am — 12:00 pm PT
Presenter:Anita Nelson, MD, Professor and Chair, Obstetrics and Gynecology,
 College of Osteopathic Medicine of the Pacific

For more information, please visit the company website at www.agiletherapeutics.com.

About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women.  Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. The company may occasionally disseminate material, nonpublic information on the company website.

Source:  Agile Therapeutics

Investor Relations Contact:  
Mary Coleman 
Agile Therapeutics
609-356-1921
mcoleman@agiletherapeutics.com

Media Relations Contact:
Glenn Silver
Lazar Partners Ltd.
646-871-8485
gsilver@lazarpartners.com